CRISPR Therapeutics AG

Short Term Long Term Short Term Comparison Long Term Comparison
  • CRSP
  • 1d-3.21%
  • 1w-9.92%
  • 1m-19.51%
  • 1y16.72%
ATH
  • ATH Price$210.04
  • ATH Date2021-01-14
  • % since ATH-72.04%
  • % to ATH257.70%
ATL
  • ATL Price$13.62
  • ATL Date2017-05-31
  • % from ATL331.13%
  • Last Low Price$38.62
  • Last Low Date2023-10-20
  • % From Last Low52.05%
IPO
  • IPO Price$15.00
  • % Current ROI USD391.47%
  • ATH Price$210.04
  • % ROI ATH 154,214.39%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CRSP"]

Key Data [addtoany]

Current price $58.72
Sector Healthcare
Industry Biotechnology
Today's High/Low $60.95/$58.47
Volume 1,459,546.00
Previous Close $60.67
52 Week High/Low $91.1/$37.55
Market Cap 5,143,916,032.00
P/E Ratio 0
Forward P/E 1 Yr. $23.36
Earnings Per Share(EPS) $-4.27
Annualized Dividend $0
$58.72
[addtoany]

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases.
The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies.
It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis.
The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014.
CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Annual Data | Millions of US $ except per share data 2019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Cash on hand $943.77$456.65$239.76$315.52$155.96-
Receivables $0.10$0.09$2.63$3.16$0.34$3
Inventory --$0$0--
Pre-Paid Expenses ------
Other Current Assets --$6$1.51$0.54$0.02
Total Current Assets $987.55$466.40$248.39$320.19$156.84$0.97
Property, Plant, And Equipment $72.83$18.50$18.86$21.03$1.33-
Long-Term Investments ------
Goodwill And Intangible Assets --$0$0--
Other Long-Term Assets $6.14$3.83$3.76$3.35$0.80$0.05
Total Long-Term Assets $79.21$22.62$22.96$24.77--
Total Assets $1,066.75$489.02$271.35$344.96$159.42$1.53
Total Current Liabilities $57.11$27.75$14.51$22$10.16$2.15
Long Term Debt --$0$0$38.34$38
Other Non-Current Liabilities $26.17$69.08$69$90.12$75.54$0.09
Total Long Term Liabilities $70.22$69.08$69$90.12--
Total Liabilities $127.33$96.82$83.51$112.12$124.03$2.23
Common Stock Net $1.85$1.58$1.24$1.22$0.18$0.12
Retained Earnings (Accumulated Deficit) $-224.71$-291.57$-125.44$-57.08$-33.91$-8.40
Comprehensive Income --$0.01$-0.03--
Other Share Holders Equity $0700000$-0800000$0.01$-0.03$-0800000$-0200000
Share Holder Equity $939.43$392.20$187.83$232.85$-29.10$-7.12
Total Liabilities And Share Holders Equity ------